Ondansetron transdermal - Starton Therapeutics
Alternative Names: CHEMIO ONDAN; CMIO-ONDANLatest Information Update: 28 Jun 2022
At a glance
- Originator ChemioCare
- Developer Starton Therapeutics
- Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting in USA (Transdermal, Patch)
- 06 Feb 2019 Chemiocare expects the US FDA response for pre-IND meeting by the end of May 2019
- 06 Feb 2019 Chemiocare plans a pre-IND meeting with the US FDA in March 2019